Oncological safety of autologous breast reconstruction after mastectomy for invasive breast cancer

BMC Cancer

Table 1 Comparison of patient- and tumour characteristics in the non-ABR and the ABR group

Variable	Non-ABR (n = 1841)		ABR (n = 485)		p-value
Variable	n	%	n	%
Age at mastectomy, median (range)	55 (23–71)		47 (24–71)		< 0.001*
- Missing data	0		0
NPI, median (range)	4.6 (2.0–9.1)		4.5 (2.0–8.2)		0.007*
- Missing data	221		42
Invasive tumour size in mm, median (range)	30 (0–180)		25 (0–160)		< 0.001*
- Missing data	105		18
In situ tumour size in mm, median (range)	49 (0–170)		49 (0–170)		0.965
- Missing data	572		132
Tumour grade					0.663
- 1	151	8	45	9
- 2	816	45	206	43
- 3	850	47	225	47
- Missing data	24		9
Lymph node status					0.020*
- Negative	739	47	229	54
- Positive	817	53	196	46
- Missing data	285		60
Lymphovascular invasion					0.945
- No	872	67	222	67
- Yes	432	33	109	33
- Missing data	537		154
Tumour type					0.290
- IDC	1360	74	372	77
- ILC	325	18	71	15
- Other	156	8	42	9
- Missing data	0		0
ER/PR					0.948
- Negative	389	21	103	22
- Positive	1424	79	374	78
- Missing data	28		8
Her-2					0.892
- Negative	1419	81	375	80
- Positive	342	19	92	20
- Missing data	80		18
Neoadjuvant treatment
- Yes	275	15	56	12	0.057
- No	1566	85	429	88
- Missing data	0		0

Variables presented with percentages are analysed using a Chi-square test. Variables summarized by medians and range are analysed using a Mann-Whitney U test. All reported p-values are two-sided
NPI Nottingham Prognostic Index, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, ER oestrogen receptor, PR progesterone receptor, Her-2 Human epidermal growth factor receptor
*denotes statistical significance (p < 0.05)

ISSN: 1471-2407